REQUEST A DEMO
Total
USD $0.00
Search more companies

Staidson (Beijing) Biopharmaceuticals Co., Ltd. (舒泰神(北京)生物制药股份有限公司) (China)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Staidson (Beijing) Biopharmaceuticals Co., Ltd. Profile Updated: March 29, 2026
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English & Chinese Download a sample report

Staidson (Beijing) Biopharmaceuticals Co., Ltd. (舒泰神(北京)生物制药股份有限公司) is an enterprise in China, with the main office in Beijing. The enterprise currently operates in the Pharmaceutical and Medicine Manufacturing sector. Staidson (Beijing) Biopharmaceuticals Co., Ltd. (舒泰神(北京)生物制药股份有限公司) was incorporated on August 16, 2002. It currently has a total number of 492 (2024) employees. From the latest financial highlights, Staidson (Beijing) Biopharmaceuticals Co., Ltd. (舒泰神(北京)生物制药股份有限公司) reported a net sales revenue drop of 30.82% in Q3C2025. Over the same period, its total assets decreased by 1.57%. In 2025, Staidson (Beijing) Biopharmaceuticals Co., Ltd. (舒泰神(北京)生物制药股份有限公司)’s net profit margin decreased by 17.39%.

Headquarters
No. 36, Jinghai 2nd Road, Beijing Economic and Technological Development Zone, Beijing
Beijing; Beijing; Postal Code: 100176

Contact Details: Purchase the Staidson (Beijing) Biopharmaceuticals Co., Ltd. (舒泰神(北京)生物制药股份有限公司) report to view the information.

Website: http://www.staidson.com

Basic Information
Total Employees:
Purchase the Staidson (Beijing) Biopharmaceuticals Co., Ltd. (舒泰神(北京)生物制药股份有限公司) report to view the information.
Outstanding Shares:
Purchase the Staidson (Beijing) Biopharmaceuticals Co., Ltd. (舒泰神(北京)生物制药股份有限公司) report to view the information.
Registered Capital:
Purchase the Staidson (Beijing) Biopharmaceuticals Co., Ltd. (舒泰神(北京)生物制药股份有限公司) report to view the information.
Financial Auditors:
Purchase the Staidson (Beijing) Biopharmaceuticals Co., Ltd. (舒泰神(北京)生物制药股份有限公司) report to view the information.
Incorporation Date:
August 16, 2002
Key Executives
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Ownership Details
Purchase this report to view the information.
31.01%
Purchase this report to view the information.
6.2%
Purchase this report to view the information.
5.68%
Purchase this report to view the information.
2.57%
Purchase this report to view the information.
1.96%
Subsidiaries
Beijing Caiye Health Management Co., Ltd.
100%
Beijing Nuoweikang Pharmaceutical Technology Co., Ltd.
100%
Intellimmu Biopharma Inc.
100%
Company Performance
Financial values in the chart are available after Staidson (Beijing) Biopharmaceuticals Co., Ltd. (舒泰神(北京)生物制药股份有限公司) report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency CNY. Absolute financial data is included in the purchased report.
Net sales revenue
-30.82%
Total Operating Revenue
-30.9%
Operating Profit
-334.05%
Net Profit/Loss for the Period
-304.48%
Total Assets
-1.57%
Total Equity
-16.77%
Operating Profit Margin
-17.41%
Net Profit Margin
-17.39%
Return on Equity (ROE)
-3.5%
Quick Ratio
1242.86%
Cash Ratio
1.02%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?